The purpose of this multicentric study is to assess the rehabilitative effect derived from the use of the ATLAS exoskeleton in children with neuromuscular diseases or cerebral palsy and with a level of less than 3 or less in the Functional Ambulation Classification (FAC) as a consequence of their disease, as well as the assessment of other physical, functional and quality of life parameters of interest. For this purpose, the exoskeleton will be used as a rehabilitation and walking assistance tool. Before starting the study programme and if deemed necessary, a preliminary phase consisting of 1 to 3 sessions will be carried out during which the patient will be shown the exoskeleton for the first time and it will be considered whether any improvements to the different parts of the device or the software are necessary to increase the ergonomics and comfort of the patient.
The objectives of the study are: * Objective 1: To assess the safety and physical and physiological tolerance of the child to the activity performed with the exoskeleton in the rehabilitation sessions. * Objective 2: * To assess the safety of a progressive treatment algorithm to achieve the safe progression of patients throughout the therapy * To assess whether an improvement is achieved in parameters related to the physical rehabilitation of the patient using the exoskeleton, in respiratory capacity, self-perceived quality of life (physical and emotional well-being and self-esteem) as well as to assess the effectiveness of a psychological intervention to provide support in coping with the situation of using the device for the first time in those children who have not used it before. The time period of the study will be as long as necessary to reach the desired number of participants, in this case 10 children (N=10). The participants will be patients affected by neuromuscular diseases or cerebral palsy and will be selected on the basis of the following inclusion/exclusion criteria: Inclusion criteria: 1. Children with neuromuscular disease or cerebral palsy who present gait disturbances or no gait disturbance. 2. Children between 3 and 11 years of age. Exclussion criteria: not fulfil the usage criteria of the device.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
10
The participant will attend the laboratory every week, two days a week. The therapy will consist of the use of the exoskeleton for rehabilitative purposes. At the end of each three-month period, each patient's data will be monitored.
MarsiCare
Arganda, Madrid, Spain
Muscular balance
Strength measured in Newtons with a Hand-Held Dinamometer for elbow flexion, neck lateralization, ankle plantarflexion and dorsiflexion, knee flexion and extension.
Time frame: 1 month
Expanded Hammersmith Functional Motor Scale
Motor functionality measured for children with Spinal Muscular Atrophy
Time frame: 3 months
Gross Motor Function Measure 88 (GMFM-88)
Motor functionality measured for children with Cerebral Palsy.
Time frame: 3 months
Respiratory rate
Respiratory rate measured manually in breaths per minute using chronometer
Time frame: 1 day
Heart rate
Measured in beats per minute using vital sign monitor
Time frame: 1 day
Oxigen Saturation
Measured in %O2 using vital sign monitor
Time frame: 1 day
Blood preasure
measured in mmHg with a sphyngomanometer
Time frame: 1 day
Respiratory functional parameters
Measured by Spirometer (volumes measured in litres and pressures in mmHg)
Time frame: 3 months
Quality of life assessment
Quality of life iof the children measured using the KINDL questionnaire.
Time frame: 3 months
Joint range of motion
Range of motion in degrees of hip, knee and ankle movements using a manual goniometer.
Time frame: 1 month
Revised Upper Limb Module (RULM)
Upper limb quality of movement using RULM scale for Spinal Muscular Atrophy children
Time frame: 3 months
Quality Upper Extremity Skill test (QUEST)
Upper limb quality of movement using QUEST scale for cerebral palsy children
Time frame: 3 months
The Functional Independence Measure for Children (WeeFim)
WeeFim scale for CP children.
Time frame: 3 months
Egen Klassifikation
Functional ability measured using EK2 scale for SMA
Time frame: 3 months
Skin integrity
Skin alterations assessing their localization, size (centimeters), redness and temperature increase.
Time frame: 1 day
Fatigue
Patient fatigue measured by Borg fatigue scale for children ages
Time frame: 1 day
Pain assessment
Patient pain measured by EVA faces scale for children ages
Time frame: 1 day
Peak Flow cough
Measured in litres per minute using a Peak flowmeter
Time frame: 1 week
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.